Vismodegib for Treatment of Periocular Basal Cell Carcinoma – 6-Year Experience from a Tertiary Cancer Center

Detalhes bibliográficos
Autor(a) principal: Xavier, C
Data de Publicação: 2021
Outros Autores: Lopes, E, Bexiga, C, Moura, C, Gouveia, E, Duarte, AF
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10400.17/4284
Resumo: Background: The treatment of advanced periocular basal cell carcinomas becomes a challenge as surgery may involve highly mutilating procedures. Vismodegib is the first selective hedgehog inhibitor approved for the treatment of locally advanced tumors or metastatic disease. Objective: Analyze the results of treatment with vismodegib for advanced periocular basal cell carcinomas in a real-life setting of a reference center between 2014 and 2020. Methods: Retrospective longitudinal study. The patient's demographic profile, comorbidities, tumor characteristics, and treatment outcomes were analyzed. Results: A total of 13 patients were included. Median follow-up and treatment duration were 15.9 and 10.5 months, respectively. Objective clinical response rate was 76.9%: 30.8% had a complete response and 46.2% a partial response. The median duration of response was 13 months. Progressive disease was observed in 38.5% of cases, with a median of 19 months after the beginning of treatment. Eighty-four percent of the patients had at least one adverse event, and 61.54% needed to interrupt treatment temporarily or permanently to increase tolerability. Study limitations: Being a retrospective study in a real-life setting, the evaluation of objective clinical response was subjective to physician appreciation. Conclusion: Vismodegib is a safe and effective treatment for locally advanced basal cell carcinoma. To prevent recurrences, the drug should be used continually when tolerated. The role of neoadjuvant vismodegib before surgery is being investigated and might add an important step in searching for a definitive treatment for these cases.
id RCAP_51b92cc6b30d89713fa5e1601dfb120a
oai_identifier_str oai:repositorio.chlc.min-saude.pt:10400.17/4284
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Vismodegib for Treatment of Periocular Basal Cell Carcinoma – 6-Year Experience from a Tertiary Cancer CenterCarcinoma, basal cellHedgehog proteinsSkin neoplasmsHSAC OFTBackground: The treatment of advanced periocular basal cell carcinomas becomes a challenge as surgery may involve highly mutilating procedures. Vismodegib is the first selective hedgehog inhibitor approved for the treatment of locally advanced tumors or metastatic disease. Objective: Analyze the results of treatment with vismodegib for advanced periocular basal cell carcinomas in a real-life setting of a reference center between 2014 and 2020. Methods: Retrospective longitudinal study. The patient's demographic profile, comorbidities, tumor characteristics, and treatment outcomes were analyzed. Results: A total of 13 patients were included. Median follow-up and treatment duration were 15.9 and 10.5 months, respectively. Objective clinical response rate was 76.9%: 30.8% had a complete response and 46.2% a partial response. The median duration of response was 13 months. Progressive disease was observed in 38.5% of cases, with a median of 19 months after the beginning of treatment. Eighty-four percent of the patients had at least one adverse event, and 61.54% needed to interrupt treatment temporarily or permanently to increase tolerability. Study limitations: Being a retrospective study in a real-life setting, the evaluation of objective clinical response was subjective to physician appreciation. Conclusion: Vismodegib is a safe and effective treatment for locally advanced basal cell carcinoma. To prevent recurrences, the drug should be used continually when tolerated. The role of neoadjuvant vismodegib before surgery is being investigated and might add an important step in searching for a definitive treatment for these cases.ElsevierRepositório do Centro Hospitalar Universitário de Lisboa Central, EPEXavier, CLopes, EBexiga, CMoura, CGouveia, EDuarte, AF2022-11-17T14:44:13Z20212021-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10400.17/4284engAn Bras Dermatol . 2021 Nov-Dec;96(6):712-71610.1016/j.abd.2021.04.012info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-03-10T09:46:08Zoai:repositorio.chlc.min-saude.pt:10400.17/4284Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T17:21:36.712589Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Vismodegib for Treatment of Periocular Basal Cell Carcinoma – 6-Year Experience from a Tertiary Cancer Center
title Vismodegib for Treatment of Periocular Basal Cell Carcinoma – 6-Year Experience from a Tertiary Cancer Center
spellingShingle Vismodegib for Treatment of Periocular Basal Cell Carcinoma – 6-Year Experience from a Tertiary Cancer Center
Xavier, C
Carcinoma, basal cell
Hedgehog proteins
Skin neoplasms
HSAC OFT
title_short Vismodegib for Treatment of Periocular Basal Cell Carcinoma – 6-Year Experience from a Tertiary Cancer Center
title_full Vismodegib for Treatment of Periocular Basal Cell Carcinoma – 6-Year Experience from a Tertiary Cancer Center
title_fullStr Vismodegib for Treatment of Periocular Basal Cell Carcinoma – 6-Year Experience from a Tertiary Cancer Center
title_full_unstemmed Vismodegib for Treatment of Periocular Basal Cell Carcinoma – 6-Year Experience from a Tertiary Cancer Center
title_sort Vismodegib for Treatment of Periocular Basal Cell Carcinoma – 6-Year Experience from a Tertiary Cancer Center
author Xavier, C
author_facet Xavier, C
Lopes, E
Bexiga, C
Moura, C
Gouveia, E
Duarte, AF
author_role author
author2 Lopes, E
Bexiga, C
Moura, C
Gouveia, E
Duarte, AF
author2_role author
author
author
author
author
dc.contributor.none.fl_str_mv Repositório do Centro Hospitalar Universitário de Lisboa Central, EPE
dc.contributor.author.fl_str_mv Xavier, C
Lopes, E
Bexiga, C
Moura, C
Gouveia, E
Duarte, AF
dc.subject.por.fl_str_mv Carcinoma, basal cell
Hedgehog proteins
Skin neoplasms
HSAC OFT
topic Carcinoma, basal cell
Hedgehog proteins
Skin neoplasms
HSAC OFT
description Background: The treatment of advanced periocular basal cell carcinomas becomes a challenge as surgery may involve highly mutilating procedures. Vismodegib is the first selective hedgehog inhibitor approved for the treatment of locally advanced tumors or metastatic disease. Objective: Analyze the results of treatment with vismodegib for advanced periocular basal cell carcinomas in a real-life setting of a reference center between 2014 and 2020. Methods: Retrospective longitudinal study. The patient's demographic profile, comorbidities, tumor characteristics, and treatment outcomes were analyzed. Results: A total of 13 patients were included. Median follow-up and treatment duration were 15.9 and 10.5 months, respectively. Objective clinical response rate was 76.9%: 30.8% had a complete response and 46.2% a partial response. The median duration of response was 13 months. Progressive disease was observed in 38.5% of cases, with a median of 19 months after the beginning of treatment. Eighty-four percent of the patients had at least one adverse event, and 61.54% needed to interrupt treatment temporarily or permanently to increase tolerability. Study limitations: Being a retrospective study in a real-life setting, the evaluation of objective clinical response was subjective to physician appreciation. Conclusion: Vismodegib is a safe and effective treatment for locally advanced basal cell carcinoma. To prevent recurrences, the drug should be used continually when tolerated. The role of neoadjuvant vismodegib before surgery is being investigated and might add an important step in searching for a definitive treatment for these cases.
publishDate 2021
dc.date.none.fl_str_mv 2021
2021-01-01T00:00:00Z
2022-11-17T14:44:13Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10400.17/4284
url http://hdl.handle.net/10400.17/4284
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv An Bras Dermatol . 2021 Nov-Dec;96(6):712-716
10.1016/j.abd.2021.04.012
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Elsevier
publisher.none.fl_str_mv Elsevier
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799131310968537088